• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    How Investors Are Reacting To LeMaitre Vascular (LMAT) Slower Projected Revenue Growth And Mixed Earnings Track Record

    Simply Wall St·08/04/2026 21:24:39
    語音播報
    • LeMaitre Vascular (NASDAQ: LMAT) recently reported quarterly results following its scheduled earnings announcement, after analysts had projected 11.5% year-on-year revenue growth, slower than the prior year’s increase and against a mixed history of meeting estimates.
    • This shift in expected growth, combined with the company’s uneven record versus analyst forecasts over the last two years, has sharpened attention on how reliably LeMaitre can convert its market opportunities into consistent financial performance.
    • We’ll now examine how the anticipated 11.5% revenue growth and recent earnings announcement shape LeMaitre Vascular’s broader investment narrative.

    AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

    LeMaitre Vascular Investment Narrative Recap

    To own LeMaitre Vascular, you need to believe its niche vascular portfolio can support steady growth despite moderating near term revenue expectations and mixed earnings surprises. The current 11.5% consensus growth forecast does not materially alter the near term catalyst, which remains execution on guidance, but it does keep the biggest risk in focus: whether recent volume and pricing gains are sustainable without relying on temporary boosts.

    The most relevant recent development is LeMaitre’s raised full year 2026 guidance to US$277 million to US$283 million in sales and US$2.93 to US$3.08 in EPS, which the upcoming earnings will be measured against. How closely actual results track these higher targets will influence confidence in management’s ability to balance price increases, international expansion and product mix, while managing risks around reimbursement pressure and regulatory complexity.

    Yet despite this stronger outlook, investors should be aware that pricing power could prove more limited than...

    Read the full narrative on LeMaitre Vascular (it's free!)

    LeMaitre Vascular's narrative projects $337.1 million revenue and $84.2 million earnings by 2029. This requires 9.6% yearly revenue growth and about a $21.8 million earnings increase from $62.4 million today.

    Uncover how LeMaitre Vascular's forecasts yield a $118.75 fair value, a 15% upside to its current price.

    Exploring Other Perspectives

    LMAT 1-Year Stock Price Chart
    LMAT 1-Year Stock Price Chart

    Three fair value estimates from the Simply Wall St Community span roughly US$71.68 to US$124 per share, highlighting very different views on upside. Set against expectations for moderating revenue growth, this spread underlines why you may want to compare several independent takes on LeMaitre’s prospects.

    Explore 3 other fair value estimates on LeMaitre Vascular - why the stock might be worth 31% less than the current price!

    Decide For Yourself

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Ready For A Different Approach?

    Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.